Physician profile
Xiangyang Li
NPI 1497719132
$165,688.22
in general payments reported to CMS, 2019-2025
39 companies · $3,374 in 2025
The $3,374 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $10K · 2021: $17K · 2022: $32K · 2023: $44K · 2024: $19K · 2025: $3,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $12K · Consulting Fee: $10K · Travel and Lodging: $5,925 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,475.00 |
| Food and Beverage | $11,896.36 |
| Consulting Fee | $10,218.50 |
| Travel and Lodging | $5,925.42 |
| Education | $133.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $63,269.02 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $54,001.64 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $22,487.43 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Idorsia Pharmaceuticals US INC | $9,385.06 | 2022-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $2,291.25 | 2019-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,818.93 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,733.19 | 2019-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $1,441.38 | 2019-2022 | |
| Lundbeck LLC | $1,437.28 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $1,313.11 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $1,302.39 | 2021-2025 | |
| Axsome Therapeutics, INC. | $799.18 | 2022-2025 | Sunosi, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $747.01 | 2019-2025 | Trintellix |
| Neos Therapeutics, LP | $648.10 | 2019-2024 | Adzenys Xr-Odt |
| Allergan, INC. | $567.35 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiangyang Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.